NCT00458913View on ClinicalTrials.gov

Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

March 31, 2012

Conditions
Malignant Mesothelioma
Interventions
DRUG

bortezomib

DRUG

cisplatin

Trial Locations (1)

SM2 5PT

Royal Marsden - Surrey, Sutton

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT00458913 - Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma | Biotech Hunter | Biotech Hunter